GSE182150 KIT LSD1 MYC inhibition 4 v 7 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE182150_KIT_LSD1_MYC inhibition_4_v_7_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE182150_KIT_LSD1_MYC inhibition_4_v_7_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE182150_KIT_LSD1_MYC inhibition_4_v_7_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE182150_KIT_LSD1_MYC inhibition_4_v_7_human_up.

Results found

Linked to

 

Label

Description

 

Gene

ral guanine nucleotide dissociation stimulator like 2

Gene

HERC2 pseudogene 2

Gene

small integral membrane protein 44

Gene

GABPB1 intronic transcript

Gene

long intergenic non-protein coding RNA 847

Gene

AMZ2 pseudogene 1

Gene

SCO-spondin, pseudogene

Gene

long intergenic non-protein coding RNA 2582

Gene

LHFPL3 antisense RNA 2

Gene

MT-ND4 pseudogene 12

  • Gene

    ral guanine nucleotide dissociation stimulator like 2


  • Gene

    HERC2 pseudogene 2


  • Gene

    small integral membrane protein 44


  • Gene

    GABPB1 intronic transcript


  • Gene

    long intergenic non-protein coding RNA 847


  • Gene

    AMZ2 pseudogene 1


  • Gene

    SCO-spondin, pseudogene


  • Gene

    long intergenic non-protein coding RNA 2582


  • Gene

    LHFPL3 antisense RNA 2


  • Gene

    MT-ND4 pseudogene 12

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.